TY - JOUR
T1 - Soft Drink Consumption and Depression Mediated by Gut Microbiome Alterations
AU - Edwin Thanarajah, Sharmili
AU - Ribeiro, Adèle H.
AU - Lee, Jaehyun
AU - Winter, Nils R.
AU - Stein, Frederike
AU - Lippert, Rachel N.
AU - Hanssen, Ruth
AU - Schiweck, Carmen
AU - Fehse, Leon
AU - Bloemendaal, Mirjam
AU - Aichholzer, Mareike
AU - Bouzouina, Aicha
AU - Uckermark, Carmen
AU - Welzel, Marius
AU - Repple, Jonathan
AU - Matura, Silke
AU - Meinert, Susanne
AU - Bang, Corinna
AU - Franke, Andre
AU - Leenings, Ramona
AU - Konowski, Maximilian
AU - Ernsting, Jan
AU - Fisch, Lukas
AU - Barkhau, Carlotta
AU - Thomas-Odenthal, Florian
AU - Usemann, Paula
AU - Teutenberg, Lea
AU - Straube, Benjamin
AU - Alexander, Nina
AU - Jamalabadi, Hamidreza
AU - Nenadic, Igor
AU - Lügering, Andreas
AU - Nitsch, Robert
AU - Kittel-Schneider, Sarah
AU - Cryan, John F.
AU - Reif, Andreas
AU - Kircher, Tilo
AU - Heider, Dominik
AU - Dannlowski, Udo
AU - Hahn, Tim
PY - 2025/11/1
Y1 - 2025/11/1
N2 - Importance: Soft drink consumption is linked to negative physical and mental health outcomes, but its association with major depressive disorder (MDD) and the underlying mechanisms remains unclear. Objective: To examine the association between soft drink consumption and MDD diagnosis and severity and whether this association is mediated by changes in the gut microbiota, particularly Eggerthella and Hungatella abundance. Design, Setting, and Participants: This multicenter cohort study was conducted in Germany using cross-sectional data from the Marburg-Münster Affective Cohort. Patients with MDD and healthy controls (aged 18-65 years) recruited from the general population and primary care between September 2014 and September 2018 were analyzed. Data analyses were conducted between May and December 2024. Main Outcomes and Measures: Primary analyses included multivariable regression and analysis of variance (ANOVA) models examining the association between soft drink consumption and MDD diagnosis and symptom severity, controlling for site and education, and Eggerthella and Hungatella abundance, controlling for site, education, and library size. Mediation analyses tested whether microbiota abundance mediated the soft drink-MDD link. Results: A total of 405 patients with MDD (275 female patients [67.9%]; mean [SD] age, 36.37 [13.33] years) and 527 healthy controls (345 female controls [65.5%]; mean [SD] age, 35.33 [13.13] years) were included. Soft drink consumption predicted MDD diagnosis (odds ratio [OR], 1.081; 95% CI, 1.008-1.159; P = .03) and symptom severity (P < .001; partial η2 [ηp2], 0.012; 95% CI, 0.004-0.035), with stronger effects in women (diagnosis: OR, 1.167; 95% CI, 1.054-1.292; P = .003; severity: P < .001; ηp2, 0.036; 95% CI, 0.011-0.062). In women, consumption was linked to increased Eggerthella (P = .007; ηp2, 0.017; 95% CI, 0.0002-0.068), but not Hungatella abundance. Mediation analyses confirmed that Eggerthella significantly mediated the soft drink-MDD association (diagnosis: P = .011; severity: P = .005), explaining 3.82% and 5.00% of the effect, respectively. Conclusions and Relevance: In this cohort study, it was found that soft drink consumption may contribute to MDD through gut microbiota alterations, notably involving Eggerthella. Public health strategies to reduce soft drink intake may help mitigate depression risk, especially among vulnerable populations; in addition, interventions for depression targeting the microbiome composition appear promising.
AB - Importance: Soft drink consumption is linked to negative physical and mental health outcomes, but its association with major depressive disorder (MDD) and the underlying mechanisms remains unclear. Objective: To examine the association between soft drink consumption and MDD diagnosis and severity and whether this association is mediated by changes in the gut microbiota, particularly Eggerthella and Hungatella abundance. Design, Setting, and Participants: This multicenter cohort study was conducted in Germany using cross-sectional data from the Marburg-Münster Affective Cohort. Patients with MDD and healthy controls (aged 18-65 years) recruited from the general population and primary care between September 2014 and September 2018 were analyzed. Data analyses were conducted between May and December 2024. Main Outcomes and Measures: Primary analyses included multivariable regression and analysis of variance (ANOVA) models examining the association between soft drink consumption and MDD diagnosis and symptom severity, controlling for site and education, and Eggerthella and Hungatella abundance, controlling for site, education, and library size. Mediation analyses tested whether microbiota abundance mediated the soft drink-MDD link. Results: A total of 405 patients with MDD (275 female patients [67.9%]; mean [SD] age, 36.37 [13.33] years) and 527 healthy controls (345 female controls [65.5%]; mean [SD] age, 35.33 [13.13] years) were included. Soft drink consumption predicted MDD diagnosis (odds ratio [OR], 1.081; 95% CI, 1.008-1.159; P = .03) and symptom severity (P < .001; partial η2 [ηp2], 0.012; 95% CI, 0.004-0.035), with stronger effects in women (diagnosis: OR, 1.167; 95% CI, 1.054-1.292; P = .003; severity: P < .001; ηp2, 0.036; 95% CI, 0.011-0.062). In women, consumption was linked to increased Eggerthella (P = .007; ηp2, 0.017; 95% CI, 0.0002-0.068), but not Hungatella abundance. Mediation analyses confirmed that Eggerthella significantly mediated the soft drink-MDD association (diagnosis: P = .011; severity: P = .005), explaining 3.82% and 5.00% of the effect, respectively. Conclusions and Relevance: In this cohort study, it was found that soft drink consumption may contribute to MDD through gut microbiota alterations, notably involving Eggerthella. Public health strategies to reduce soft drink intake may help mitigate depression risk, especially among vulnerable populations; in addition, interventions for depression targeting the microbiome composition appear promising.
UR - https://www.scopus.com/pages/publications/105020978131
U2 - 10.1001/jamapsychiatry.2025.2579
DO - 10.1001/jamapsychiatry.2025.2579
M3 - Article
C2 - 40991280
AN - SCOPUS:105020978131
SN - 0003-990X
VL - 82
SP - 1095
EP - 1102
JO - JAMA Psychiatry
JF - JAMA Psychiatry
IS - 11
ER -